Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk Mortality (b) 67% early Mortality (c) 77% Mortality (d) 84% Mortality (e) -29% c19hcq.org Corradini et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,713 patients in Italy Lower mortality with HCQ (p<0.000001) Corradini et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02742-8 Favors HCQ Favors control
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI)
Corradini et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02742-8
Corradini et al., Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy:.., Internal and Emergency Medicine, doi:10.1007/s11739-021-02742-8
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 3,044 hospitalized COVID-19 patients in Italy, showing HCQ significantly associated with survival in light, mild, and moderate cases in multivariable analysis, but not in severe cases.
risk of death, 70.2% lower, OR 0.30, p < 0.001, treatment 1,439, control 274, adjusted per study, Table S6, all patients, multivariable, RR approximated with OR.
risk of death, 67.4% lower, OR 0.33, p = 0.01, treatment 641, control 102, adjusted per study, Table S6, light condition patients, multivariable, RR approximated with OR, early treatment result.
risk of death, 76.8% lower, OR 0.23, p < 0.001, treatment 546, control 71, adjusted per study, Table S6, mild condition patients, multivariable, RR approximated with OR.
risk of death, 84.2% lower, OR 0.16, p < 0.001, treatment 184, control 64, adjusted per study, Table S6, moderate condition patients, multivariable, RR approximated with OR.
risk of death, 29.0% higher, OR 1.29, p = 0.73, treatment 68, control 37, adjusted per study, Table S6, severe condition patients, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Corradini et al., 24 Apr 2021, retrospective, Italy, peer-reviewed, 60 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Internal and Emergency Medicine (2021) 16:1005–1015 https://doi.org/10.1007/s11739-021-02742-8 IM - ORIGINAL Clinical factors associated with death in 3044 COVID‑19 patients managed in internal medicine wards in Italy: results from the SIMI‑COVID‑19 study of the Italian Society of Internal Medicine (SIMI) Elena Corradini1 · Paolo Ventura1 · Walter Ageno2 · Chiara Beatrice Cogliati3 · Maria Lorenza Muiesan4 · Domenico Girelli5 · Mario Pirisi6 · Antonio Gasbarrini7 · Paolo Angeli8 · Patrizia Rovere Querini9 · Emanuele Bosi9 · Moreno Tresoldi9 · Roberto Vettor10 · Marco Cattaneo11 · Fabio Piscaglia12 · Antonio Luca Brucato13 · Stefano Perlini14 · Paolo Martelletti15 · Roberto Pontremoli16 · Massimo Porta17 · Pietro Minuz18 · Oliviero Olivieri19 · Giorgio Sesti20 · Gianni Biolo21 · Damiano Rizzoni22 · Gaetano Serviddio23 · Francesco Cipollone24 · Davide Grassi25 · Roberto Manfredini26 · Guido Luigi Moreo27 · Antonello Pietrangelo1 · SIMI-COVID-19 Collaborators Received: 19 February 2021 / Accepted: 9 April 2021 / Published online: 24 April 2021 © Società Italiana di Medicina Interna (SIMI) 2021 Abstract During the COVID-19 2020 outbreak, a large body of data has been provided on general management and outcomes of hospitalized COVID-19 patients. Yet, relatively little is known on characteristics and outcome of patients managed in Internal Medicine Units (IMU). To address this gap, the Italian Society of Internal Medicine has conducted a nationwide cohort multicentre study on death outcome in adult COVID-19 patients admitted and managed in IMU. This study assessed 3044 COVID-19 patients at 41 referral hospitals across Italy from February 3rd to May 8th 2020. Demographics, comorbidities, organ dysfunction, treatment, and outcomes including death were assessed. During the study period, 697 patients (22.9%) were transferred to intensive care units, and 351 died in IMU (death rate 14.9%). At admission, factors independently associated with in-hospital mortality were age (OR 2.46, p = 0.000), productive cough (OR 2.04, p = 0.000), pre-existing chronic heart failure (OR 1.58, p = 0.017) and chronic obstructive pulmonary disease (OR 1.17, p = 0.048), the number of comorbidities (OR 1.34, p = 0.000) and polypharmacy (OR 1.20, p = 0.000). Of note, up to 40% of elderly patients did not report fever at admission. Decreasing P ­ aO2/FiO2 ratio at admission was strongly inversely associated with survival. The use of conventional oxygen supplementation increased with the number of pre-existing comorbidities, but it did not associate with better survival in patients with ­PaO2/FiO2 ratio < 100. The latter, significantly benefited by the early use of non-invasive mechanical ventilation. Our study identified ­PaO2/FiO2 ratio at admission and comorbidity as the main alert signs to inform clinical decisions and resource allocation in non-critically ill COVID-19 patients admitted to IMU. Keywords SARS-CoV-2 · Mortality from COVID-19 · Comorbidity · Polypharmacy · Internal medicine Abbreviations ACE Angiotensin-converting enzyme CHF Chronic heart failure Elena Corradini and Paolo Ventura contributed equally to the work. Members of the SIMI COVID-19 Collaborators are listed in the Acknowledgement section at the end of the article. * Antonello Pietrangelo antonello.pietrangelo@unimore.it CKD Chronic kidney disease COPD Chronic obstructive pulmonary disease COVID-19 Coronavirus disease 2019 CPAP Continuous positive air pressure CRF Case report..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit